BeiGene, Ltd. announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, including commercial and clinical teams, and this new location will serve as a hub for the company's operations in the region. Founded in 2010, BeiGene now counts a global team of over 8,000 colleagues across five continents.

Currently, BeiGene's European organization includes more than 270 colleagues, and the Basel office is expected to initially include 150 colleagues. The company conducts clinical trials globally and to date has enrolled patients from more than 45 countries, including 25 countries in Europe. BeiGene's BTK inhibitor zanubrutinib was approved by the European Medicines Agency in November 2021 for treatment of adults with Waldenström's macroglobulinemia and has subsequently received approvals in Great Britain and Switzerland.

In addition to the new Basel office, BeiGene has offices around the world, with key operations in Cambridge, Massachusetts and Beijing, China.